Working Life: Celgene’s Lee Heeson
August 3, 2015Medical Communications, Sales and Marketing Celgene, Lee Heeson
How did you find your way into your current role?My career has progressed from ‘carrying the bag’ for GlaxoSmithKline in …
Eleven companies accused in Romanian corruption probe
August 3, 2015Business Services, Medical Communications, Sales and Marketing China, Daily Telegraph, GSK, Roche, Romania, bribery, corruption
GSK and Roche are among eleven pharma firms being investigated for paying bribes to doctors in Romania to prescribe drugs. …
AbbVie’s Humira receives first European OK for skin condition
August 3, 2015Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab
The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …
Encouraging first results from trial of Merck’s Ebola vaccine
July 31, 2015Research and Development, Sales and Marketing Africa, EBV, Ebola, Ebola virus, Ebola virus disease, Vaccine, WHO, World Health Organisation, guinea, vaccination
The first trial of an experimental Ebola vaccine suggests it provides high protection against the disease as early as ten …
UK patients ‘self-diagnose rather than visit GP’
July 31, 2015Medical Communications GP, General Practice, internet
One in five people in the UK admit to self-diagnosing illnesses rather than making a doctor’s appointment. Research published in …
ABPI consulting on Code of Conduct changes
July 31, 2015Medical Communications, Sales and Marketing ABPI Code, PMCPA, Prescription Medicines Code of Practice Authority, code of conduct
The division of the ABPI that sets rules governing industry behaviour is consulting on changes to reflect new rules on …
Doctors ‘distrust apps developed by pharma’ – survey
July 31, 2015Medical Communications France, GPs, Germany, Healthcare Technologies, UK, chronic disease, disease management, healthcare tech
A study of GPs in three European countries show GPs feel there is a role for healthcare technologies in disease …
Depomed rejects Horizon’s latest takeover bid
July 30, 2015Sales and Marketing Depomed, horizon, mergers and acquisitions, takeovers
Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company. The Irish pharma company …
Sanofi sales boosted by rare disease and multiple sclerosis drugs
July 30, 2015Manufacturing and Production, Sales and Marketing Genzyme, Oliver Brandicourt, Sanofi, brandicourt, financial results
Sales at pharma giant Sanofi increased by 5% in the second quarter of 2016 to nearly €10 billion, its latest …
BMS to trial Opdivo in solid tumours
July 30, 2015Research and Development BMS, Bristol-Myers Squibb, Kyowa Hakko Kirin, Poteligeo, mogamulizumab, nivolumab, opdivo, solid tumours
Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination …
NICE restricts access to new hepatitis C treatments
July 29, 2015Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C
NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …
Takeda cancer drug gets EMA boost
July 29, 2015Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma
The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …
David Khougazian announced as president of Sanofi Pasteur MSD
July 29, 2015Business Services, Research and Development, Sales and Marketing MSD, Merck, Sanofi Pasteur
Sanofi Pasteur and Merck have appointed David Khougazian as president of their joint company, Sanofi Pasteur MSD. David Khougazian joined …
Dr James Shannon joins Immodulon Therapeutics board of directors
July 29, 2015Research and Development, Sales and Marketing Immodulon
Dr James Shannon has joined Immodulon as a non-executive director with immediate effect. Bringing with him 30 years’ of experience …
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Novartis forms Mereo as UK biotech spin-off
July 29, 2015Research and Development Mereo, Novartis, biotech, rare diseases
Novartis has formed a new UK biotech company by selling three investigational drugs in exchange for shares in the new …
Cambridge collaboration to boost precision medicine research
July 29, 2015Research and Development Brabaham Institute, Cambridge, R&D, collaboration
A new consortium has been launched to act as a ‘match-making’ service between pharma companies and R&D researchers to develop …
Judge rules pharma has ‘ethical’ transparency obligation – reaction
July 29, 2015Research and Development Ben Goldacre, Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, sense about science, transparency
Both sides of a bitterly contested legal battle over a major part of the industry’s transparency drive have reacted to …
Judge backs HRA in transparency legal case
July 28, 2015Research and Development EU Clinical Trial Regulation, Richmond Pharmacology, alltrials, clinical trial regulation, clinical trials, health research authority, sense about science, transparency
A judge has ruled that there are likely to be no legal grounds to block the Health Research Authority’s plans …
Lupin buys Gavis to gain first US manufacturing site
July 28, 2015Manufacturing and Production Gavis, Lupin, manufacturing, production
Indian drug manufacturer Lupin is expanding to the US by purchasing Gavis pharma for $880 million, in a major boost …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
